Updated 17 October 2024
Introduction
Please find herewith an overview of clinical trials that are ongoing in hospitals that are part of the ECFS Clinical Trials Network (CTN).
Here you will find the full list of our Clinical Trials Network CF centres.
Studies only run in our CTN sites after a formal review of the study protocol and approval by a committee of experts (comprised of both adult and paediatric specialist CF clinicians, patient organisation representatives and patient/family reviewers). This does not mean that all CTN centres will participate in a specific study. Some CTN approved studies also run in additional centres that are not part of the CTN network. A complete list of participating sites can be found on the specific www.clinicaltrials.gov (link is external) that is mentioned on each study overview sheet.
If you wish to participate in some of the trials listed here, please discuss this with your treating physician/doctor/healthcare team.
The overview lists the studies under the headings: "recruitment started" or under "recruitment finished". In addition, the studies are categorized according to the drug's mechanism of action, using the following headings:
- Genetic Therapy
- Restore CFTR Protein
- Mucociliary Clearance
- Anti-Inflammatory
- Anti-Infective
- Nutritional-GI
- Behavioural Interventions
- Observational
- Other
If you would like more detailed information on a particular study, please go to www.clinicaltrials.gov for detailed and up to date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for any additional information:
ECFS-CTN@uzleuven.be (link sends e-mail)
Overview of Studies
Recruitment Started in CTN sites:
Genetic Therapy
Restore CFTR Protein
- Vertex VX20-445-112
- Vertex VX21-121-105
- Vertex VX22-121-106
- Vertex VX22-445-122
- Enterprise Therapeutics ET-ENAC-03
- UMC Utrecht - HIT-CF-001 – CHOICES
- Vertex VX22-445-123
Anti-Infective
Anti-Inflammation
Nutritional-GI
Other
Recruitment Completed in CTN sites:
Restore CFTR Protein
- PTC 124
- PTC 124 extension + study results
- Vertex VX12-770-111+ study results
- Vertex VX11-770-110 + study results
- Vertex VX12-809-103 + study results
- Vertex VX12-809-104 + study results
- Vertex VX11-770-108 + study results
- Vertex VX-809 alone and combined with VX-770 + study results
- Vertex VX11-661-101 + study results
- Vertex VX12-770-112 (extension) + study results
- Vertex VX12-809-105 (extension) + study results
- Vertex VX11-770-109 (extension) + study results
- PTC124-GD-021-CF (ACT CF)
- Novartis CQBW25X2101 + study results
- Vertex VX14-661-106 + study results
- Vertex VX14-661-107 + study results
- Vertex VX14-661-108 + study results
- Vertex VX14-809-109 + study results
- Galapagos GLPG1837-CL-202
- ProQR PQ-010-002 + study results
- PTC124-GD-021e-CF (Extension study)
- Vertex VX15-809-110 (Extension study)
- Vertex VX14-661-109
- Vertex VX15-371-101
- Galapagos GLPG1837-CL-201
- Vertex VX14-661-110 (Extension study)
- Bayer 17020
- ProQR PQ-010-001 + study results
- Vertex VX15-770-123
- Vertex VX15-440-101
- Galapagos-GLPG2222-CL-201
- Galapagos GLPG2222-CL-202
- Vertex VX16-659-001partD
- Vertex VX16-445-001
- Proteostatis PTI-428-01
- Vertex VX16-659-101
- Galapagos GLPG2737-CL-202
- Flatley FDL169-2015-04
- Vertex VX17-659-102
- Vertex VX17-659-103
- Vertex VX17-445-102
- Vertex VX17-445-103
- Vertex VX16-661-115
- Galapagos GLPG2737-CL-105
- Vertex VX17-659-105
- Vertex VX17-661-116
- Vertex VX17-445-105
- Vertex VX18-121-101
- Vertex VX16-809-121
- Flatley FDL169-2018-10
- Proteostasis PTI-808-01
- Proteostasis PTI-801-01
- Vertex VX18-445-109
- Vertex VX18-445-106
- Vertex VX18-445-104
- Vertex VX18-445-110
- Vertex VX19-445-107
- Vertex VX18-445-113
- Vertex VX19-445-116
- Vertex VX20-445-119
- Vertex VX20-445-118
- Vertex VX19-445-117
- Vertex VX20-445-111
- Eloxx EL-004
- Vertex VX15-770-124
- Abbvie M19-530
- Vertex VX19-445-115
- Vertex VX20-445-126
- Vertex VX20-445-121
- Vertex VX15-770-126
- Abbvie M19-771
- Vertex VX20-121-102
- Vertex VX20-121-103
- Vertex VX21-445-124
- Vertex VX21-445-125
- Vertex VX20-121-104
Mucociliary Clearance
- SPX-101-CF-201
- SHIP-002
- Algipharma SMR2984
- Pharmaxis DPM-CF-204 + study results
- Pharmaxis DPM-CF-303 (adults) + study results
- Novartis CQBW276X2201
- Boehringer 1399-0003
- Ionis ION-827359-CS1
Anti-Infective
- MPEX Pharmaceuticals: MPEX-209
- Insmed Arikace TR02-108
- Novartis CTBM100C2401 + study results
- Gilead GS-US-205-0162 "Alpine"
- Gilead GS-US-205-0160 "PALS" + study results
- Insmed Arikace TR02-110 (extension) + study results
- Novartis CTBM100C2401E1 (extension) + study results
- Mukoviszidose Institut gGmbH: Efficacy Study of IgY (Antibody Against Pseudomonas aeruginosa) in Cystic Fibrosis Patients (PsAer-IgY)
- Novartis CTBM100C2304 EARLY study (Tobi in children) + study results
- TORPEDO-CF
- Alaxia ALX-009-CL-038
- cASPerCF
- Synspira SNSP113-19-201
- BiomX BMX-04-001
Anti-Inflammatory and Anti-Infective
Anti-Inflammatory
- GSK CF2110399 - includes Study Results
- Corbus JBT101-CF-001 + study results
- Celtaxsys CTX-4430-CF-201
- Gilead GS-US-404-1808
- Corbus JBT101-CF-002